A Norwegian nationwide cohort study showed that in newly diagnosed HF patients, 1-year adherence to dual or triple HF therapies was low and 2- to 5-year persistence was inadequate.
ESC 2022 Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.
ESC 2022 Prof. Jhund talks about the findings and implications from a pooled analysis of DAPA-HF and DELIVER with dapagliflozin in HF patients covering the entire LVEF spectrum.
ESC 2022 The DELIVER trial shows that dapagliflozin reduced the risk of CV death or worsening HF in patients with HFmrEF or HFpEF, with no attenuation of treatment benefit in patients with the highest EF.
ESC 2022 A pooled analysis of DAPA-HF and DELIVER was undertaken to examine the effect of dapagliflozin in patient with heart failure across the entire spectrum of ejection fraction.
ESC 2022 The PERSPECTIVE trial showed that sacubitril/valsartan, compared to valsartan, does not impair cognitive function or cause accumulation of amyloid β-peptides in the brain in patients with HFpEF or HFmrEF.
Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.
ACC 2022 This randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.
ACC 2022 In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium (K+) compared to placebo, but also in a lower risk of hyperkalemia events and in enablement of RAASi therapy in HFrEF patients on RAASi therapy.
ACC 2022 Although a reduction in sodium intake in HF patients did not result in a reduction of all-cause mortality of CV hospitalization compared to usual care, patient-centered outcomes were improved.
ACC 2022 What are the findings of the DIAMOND trial with the potassium binder patiromer in patients with HFrEF who were on RAASi therapy?
ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.